Jackie Grant

Jackie Grant is Vice President, Research Analyst and Client Portfolio Manager at Ariel Investments, where she is part of the domestic equity research team, serves as a liaison for domestic strategies, and works as an industry generalist. Ariel’s public materials describe the firm’s style as long-term, fundamental, bottom-up research, with “Active Patience,” independent thinking, and focused expertise as core values.

Before Ariel, Grant was a Principal at Abingworth, now part of Carlyle, a transatlantic life sciences venture capital firm. Abingworth announced her appointment on October 23, 2018, saying she would be based in Boston and work across the Boston, London, and Menlo Park offices to evaluate new opportunities and support existing venture investments.

Earlier in her career, Grant was a Senior Associate at SV Health Investors and worked in Genentech’s Business Development Group, where she focused on neuroscience partnering. Abingworth said her transaction experience included technology and platform in-licenses and research collaborations across multiple therapeutic areas and deal structures.

Grant earned a BS in biology from Boston College and both an MBA and PhD in neuroscience from Stanford University. Ariel also lists her as an executive fellow at Harvard Business School, where she lectures on investment strategy and board governance; HBS announced her in its 2023-2024 Executive Fellows cohort, collaborating on the MBA elective Entrepreneurship in the Life Sciences.

• At Ariel, Grant works within a domestic equities platform built around long-term value investing. Ariel states: “Our portfolios are built to drive long-term value, not short-term results.”
• Ariel describes its investment discipline as fundamental, bottom-up research: “Our contrarian views result from meticulous, fundamental, bottom-up research.”
• Grant’s current role is not presented as venture capital deal sourcing; she is listed as a research analyst and client portfolio manager for domestic strategies.
• Her prior Abingworth work centered on private biotech companies, especially neuroscience, ophthalmology, rare disease, and gene therapy.
• Abingworth’s seed and early-stage strategy emphasizes company building beyond capital: negotiating academic licenses, defining science and business strategy, recruiting senior management, and incubating young biotech companies.
• In her 2020 Nature Biotechnology correspondence, Grant argued for more racial diversity in biotech venture capital and described herself as one of few female racial minorities in biotech VC.